For people with severe allergy that is triggered by for example nuts or insect bites, it is vital to always bring a dose of adrenaline (epinephrine) to be on the safe side. Unfortunately, there are only bulky and hard-to-use adrenaline injectors on the market today.
These circumstances, together with the widespread feeling of discomfort around needles, has led to poor patient practice. According to a study in published in Annals of Allergy, Asthma & Immunology, more than 30 percent of persons with adrenaline prescriptions leave their injector at home. Another study published in the Journal of Family Practice reveals that needle phobia is a neglected diagnose that affects around 10 percent of all Americans.
Klaria is developing a novel adrenaline treatment for anaphylactic shock based on the company’s unique film technology, that is well suited to solve the problems associated with current adrenaline products. A stamp-sized film that attaches to the oral mucosa is completely needle-free and much easier to carry around and use. This is true for both allergy patients and their caregivers, including parents with children that suffer from severe allergies.
Klaria’s KL-01401 project to develop and commercialize an acute adrenaline treatment is a collaboration with Purdue Pharma. Purdue is one of the world’s largest pharmaceutical companies with a global outreach through a network that also includes NAPP Pharmaceuticals and Mundipharma.
In addition to the adrenaline project, Klaria is also collaborating with Purdue to develop a product for acute treatment of opioid overdose.